NO339364B1 - Humant immunglobulin som spesifikt bindes til det humane EpCAM-antigen, sammensetning omfattende dette, samt anvendelse for fremstilling av et medikament for behandling av tumorsykdom. - Google Patents

Humant immunglobulin som spesifikt bindes til det humane EpCAM-antigen, sammensetning omfattende dette, samt anvendelse for fremstilling av et medikament for behandling av tumorsykdom. Download PDF

Info

Publication number
NO339364B1
NO339364B1 NO20064136A NO20064136A NO339364B1 NO 339364 B1 NO339364 B1 NO 339364B1 NO 20064136 A NO20064136 A NO 20064136A NO 20064136 A NO20064136 A NO 20064136A NO 339364 B1 NO339364 B1 NO 339364B1
Authority
NO
Norway
Prior art keywords
cancer
epcam
immunoglobulin
administration
days
Prior art date
Application number
NO20064136A
Other languages
English (en)
Norwegian (no)
Other versions
NO20064136L (no
Inventor
Mathias Locher
Nadja Prang
Cornelia Quadt
Malte Peters
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of NO20064136L publication Critical patent/NO20064136L/no
Publication of NO339364B1 publication Critical patent/NO339364B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20064136A 2004-02-13 2006-09-13 Humant immunglobulin som spesifikt bindes til det humane EpCAM-antigen, sammensetning omfattende dette, samt anvendelse for fremstilling av et medikament for behandling av tumorsykdom. NO339364B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (2)

Publication Number Publication Date
NO20064136L NO20064136L (no) 2006-11-07
NO339364B1 true NO339364B1 (no) 2016-12-05

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064136A NO339364B1 (no) 2004-02-13 2006-09-13 Humant immunglobulin som spesifikt bindes til det humane EpCAM-antigen, sammensetning omfattende dette, samt anvendelse for fremstilling av et medikament for behandling av tumorsykdom.

Country Status (23)

Country Link
US (3) US20050180979A1 (cg-RX-API-DMAC10.html)
EP (2) EP1713830B1 (cg-RX-API-DMAC10.html)
JP (1) JP5220315B2 (cg-RX-API-DMAC10.html)
KR (1) KR101236224B1 (cg-RX-API-DMAC10.html)
CN (1) CN1976951B (cg-RX-API-DMAC10.html)
AT (1) ATE437186T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005215874B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0507660A (cg-RX-API-DMAC10.html)
CA (1) CA2555694C (cg-RX-API-DMAC10.html)
DE (1) DE602005015544D1 (cg-RX-API-DMAC10.html)
DK (1) DK1713830T3 (cg-RX-API-DMAC10.html)
EA (1) EA011951B1 (cg-RX-API-DMAC10.html)
ES (1) ES2328159T3 (cg-RX-API-DMAC10.html)
IL (1) IL177069A (cg-RX-API-DMAC10.html)
MX (1) MXPA06008942A (cg-RX-API-DMAC10.html)
NO (1) NO339364B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ549125A (cg-RX-API-DMAC10.html)
PL (1) PL1713830T3 (cg-RX-API-DMAC10.html)
PT (1) PT1713830E (cg-RX-API-DMAC10.html)
SI (1) SI1713830T1 (cg-RX-API-DMAC10.html)
UA (1) UA87128C2 (cg-RX-API-DMAC10.html)
WO (1) WO2005080428A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200606083B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004068110A2 (en) 2003-01-24 2004-08-12 University Of Utah Methods of predicting mortality risk by determining telomere length
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
RU2434640C2 (ru) * 2006-02-09 2011-11-27 Микромет Аг Лечение метастатического рака молочной железы
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
CN101970497B (zh) * 2007-04-04 2017-05-10 希格马托制药工业公司 抗‑EpCAM抗体及其用途
ES2433718T3 (es) 2008-12-22 2013-12-12 University Of Utah Research Foundation PCR multiplex monocromática cuantitativa
US20120252022A1 (en) * 2009-09-21 2012-10-04 Paul Walfish Methods and compositions for the diagnosis and treatment of thyroid cancer
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
CN103387988B (zh) * 2012-09-24 2016-01-06 厦门大学 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法
JP6546158B2 (ja) 2013-05-22 2019-07-17 テロメア ダイアグノスティクス インコーポレイテッド 短いテロメアの存在量の測定
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
US11046763B2 (en) * 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2016108954A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
CN110035768A (zh) 2016-07-26 2019-07-19 泰莎治疗私人有限公司 嵌合抗原受体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
JP3876002B2 (ja) * 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
WO2003099205A2 (en) * 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEWIS L.D., "Technology evaluation: ING-1, XOMA", Current Opinion in Molecular Therapeutics, vol. 5, no. 4, 2003, side 433-436, Dated: 01.01.0001 *

Also Published As

Publication number Publication date
NZ549125A (en) 2008-09-26
ZA200606083B (en) 2007-10-31
EP2107071A3 (en) 2009-12-30
EA200601386A1 (ru) 2007-06-29
JP2008500277A (ja) 2008-01-10
EP1713830B1 (en) 2009-07-22
US20070274982A1 (en) 2007-11-29
ES2328159T3 (es) 2009-11-10
PT1713830E (pt) 2009-10-19
EP2107071A2 (en) 2009-10-07
JP5220315B2 (ja) 2013-06-26
IL177069A0 (en) 2006-12-10
ATE437186T1 (de) 2009-08-15
US20120294873A1 (en) 2012-11-22
PL1713830T3 (pl) 2010-01-29
WO2005080428A3 (en) 2005-11-10
CA2555694A1 (en) 2005-09-01
IL177069A (en) 2010-11-30
US20050180979A1 (en) 2005-08-18
NO20064136L (no) 2006-11-07
HK1096103A1 (en) 2007-05-25
DK1713830T3 (da) 2009-10-12
MXPA06008942A (es) 2007-01-26
CN1976951B (zh) 2012-03-14
EA011951B1 (ru) 2009-06-30
UA87128C2 (ru) 2009-06-25
BRPI0507660A (pt) 2007-07-17
KR101236224B1 (ko) 2013-02-22
AU2005215874B2 (en) 2011-01-27
KR20070009988A (ko) 2007-01-19
WO2005080428A2 (en) 2005-09-01
EP1713830A2 (en) 2006-10-25
SI1713830T1 (sl) 2009-10-31
AU2005215874A1 (en) 2005-09-01
DE602005015544D1 (de) 2009-09-03
CA2555694C (en) 2013-04-16
CN1976951A (zh) 2007-06-06

Similar Documents

Publication Publication Date Title
US20120294873A1 (en) ANTI-EpCAM IMMUNOGLOBULINS
KR102349056B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
US7794713B2 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
ES2782834T3 (es) Uso de moléculas inhibidoras de semaforina-4D en combinación con una terapia inmunomoduladora para inhibir el crecimiento tumoral y la metástasis
US20220265844A1 (en) Dosing regimens for anti-tf-antibody drug-conjugates
EP3645040A1 (en) Use of anti-fam19a5 antibodies for treating cancers
US10507242B2 (en) Combination therapy for treating breast cancer
CN112584872A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的用途
TW202523359A (zh) 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
CN121311246A (zh) 癌症治疗与预防的组合疗法
JP2019014724A (ja) 併用療法
CA2581061A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
Garrett Peptide-based B-cell epitope vaccines targeting HER-2/neu
HK1096103B (en) Anti-epcam immunoglobulins
HK40130006A (zh) 通过施用抗her2抗体-药物缀合物治疗her2突变的癌
CN115607663A (zh) 抗pd-1抗体在治疗原发纵隔大b细胞淋巴瘤中的应用
CN115607662A (zh) 抗pd-1抗体在治疗腺泡状软组织肉瘤中的应用
HK40051932A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AMGEN RESEARCH (MUNICH) GMBH, DE

MM1K Lapsed by not paying the annual fees